AUTHORS
Carter Samuel Bass, BS, Roland Bruno Walter, MD, PhD, MS2, Brenda M Sandmaier, MD3, Joachim Deeg, MD4, Bart L Scott, MD5, Masumi Ueda Oshima, MD, MA6, Boglarka Gyurkocza, MD7, Lorenzo Iovino, MD, PhD8, Naveed Ali, MD9, Mohamed Sorror, MD, MS10, Ann Dahlberg, MD11, Colleen Delaney, MD, MS12, Cindy Wing Mei, BS13, Grace Elizabeth Rossi, BS14, Sarah M Mahan, MPH15, Phuong T Vo, MD16, Filippo Milano I, MD, PhD17
AFFILIATIONS
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
12 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States
14 Fred Hutchinson Cancer Center, Seattle, Washington, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States
16 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
17 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
ABSTRACT
Background
Melphalan (Mel)-based conditioning is one of the most widely used platforms for allogeneic hematopoietic cell transplantation (allo-HCT), but regimen-related toxicity (RRT) remains a major limitation in its use. Treosulfan (Treo)-based conditioning may offer a more favorable toxicity profile, but head-to-head comparative data remain limited. To test the hypothesis that Treo reduces gastrointestinal (GI) RRT while yielding comparable disease control and survival outcomes, we retrospectively analyzed adult patients undergoing allo-HCT for AML or MDS with either Treo- or Mel-based conditioning.
Methods
A total of 388 adult patients with AML (n=218) or MDS (n=170) who underwent first allo-HCT between December 2007 and December 2024 were included in this analysis. Patients received conditioning with either Mel (n=205) or Treo (n=183) combined with fludarabine (90-160 mg/m2) with or without low-dose total body irradiation (TBI; 2-3 Gy). In the Mel group, patients received a cumulative Mel dose of 100 mg/m2 (n=157) or 140 mg/m2 (n=48); in the Treo group, patients received a cumulative Treo dose of 30 g/m2 (n=19) or 42 g/m2 (n=164). GI RRT was assessed based on total parenteral nutrition (TPN) or patient-controlled analgesia (PCA) requirement prior to day +28, as well as grade III-IV oral mucositis. Overall survival (OS) and relapse-free survival (RFS) were estimated using Kaplan-Meier methods; relapse, non-relapse mortality (NRM), and graft-versus-host disease (GVHD) were analyzed using competing risk models. Multivariable models adjusted for factors that differed significantly between groups.
Results
Patients in the Mel group were significantly older (median age 65 vs. 56 years, p<0.001) and were transplanted more recently (median year of transplant 2020 vs. 2015, p<0.001) than those in the Treo group. Mel patients more frequently received HLA-mismatched unrelated donor HCT (26% vs. 5%, p<0.001), whereas Treo patients more frequently received HLA-haploidentical (13% vs. 4%, p=0.005) and HLA-matched related donor HCT (31% vs. 13%, p<0.001). Post-transplant cyclophosphamide (PTCy) was used more frequently for GVHD prophylaxis in the Mel group (30% vs. 13%, p<0.001), while Treo patients more frequently received methotrexate (34% vs. 17%, p<0.001). The use of TBI was similar between groups (77% vs. 78%, p=0.80). Disease risk and measurable residual disease status were also similar.
Overall, Treo was associated with significantly lower GI RRT burden, including reduced TPN use (26% vs. 50%, p<0.001), PCA requirement (20% vs. 34%, p=0.004), and grade III-IV oral mucositis (18% vs. 34%, p<0.001). Treo was also associated with reduced incidence of grade II-IV acute GVHD (at day +100: 59% [95% CI: 51-65%] vs. 69% [62-75%], p=0.021), grade II-IV acute GVHD of the gut (at day +100: 11% [7-16%] vs. 20% [15-26%], p=0.015), and moderate-to-severe chronic GVHD (at 3 years: 26% [19-33%] vs. 42% [35-50%], p<0.001). These associations remained statistically significant after multivariable adjustment (acute GVHD: HR=0.74 [95% CI: 0.54-1.00], p=0.049; gut acute GVHD: HR=0.50 [0.26-0.95], p=0.035; chronic GVHD: HR=0.53 [0.32-0.87], p=0.012).
No significant differences were observed between groups in OS (at 3 years: Treo 58% [51–66%] vs. Mel 57% [50–64%], p=0.60) or RFS (at 3 years: 54% [47–62%] vs. 53% [46–61%], p>0.90), including after multivariable adjustment (OS: HR=0.96 [0.65-1.40], p=0.80; RFS: HR=1.01 [0.70–1.44], p>0.90). Cumulative incidence of relapse did not differ significantly between groups (at 3 years: Treo 30% [23–37%] vs. Mel 22% [17–28%], p=0.06), including after multivariable adjustment (HR=1.37 [0.86–2.18], p=0.20). Conversely, the cumulative incidence of NRM was lower with Treo (at 3 years: 16% [11–22%] vs. 25% [19–31%], p=0.031), although this difference was not significant after multivariable adjustment (HR=0.65 [0.37–1.12], p=0.12).
Conclusions
In adult patients with AML or MDS, Treo-based conditioning was associated with lower RRT burden than Mel-based conditioning without significant differences in survival. Treo was also associated with a lower incidence of acute and chronic GVHD despite less frequent use of PTCy-based prophylaxis. Altogether, our data suggest that Treo may be favorable for frail or comorbid patients to reduce transplant-related complications, supporting further prospective comparisons of Treo- and Mel-based conditioning.
DISCLOSURES
Carter Samuel Bass, BS: No relevant conflicts of interest to declare.